Literature DB >> 19192429

The failing diabetic heart: focus on diastolic left ventricular dysfunction.

Loek van Heerebeek1, Aernout Somsen, Walter J Paulus.   

Abstract

Diabetes mellitus (DM) is highly prevalent and is an important risk factor for congestive heart failure (HF). Increased left ventricular (LV) diastolic stiffness is recognized as the earliest manifestation of DM-induced LV dysfunction, but its pathophysiology remains incompletely understood. Mechanisms whereby DM increases LV diastolic stiffness differ between HF with normal LV ejection fraction (EF) (HFNEF) and HF with reduced LVEF (HFREF). In diabetic HFREF, fibrosis and deposition of advanced glycation end products (AGEs) are the most important contributors to high LV diastolic stiffness, whereas in diabetic HFNEF, elevated resting tension of hypertrophied cardiomyocytes is the most important contributor to high LV diastolic stiffness. As HF mortality remains high in DM despite proven efficacy of current treatments, better understanding of the pathophysiology of high LV diastolic stiffness could be beneficial for novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19192429     DOI: 10.1007/s11892-009-0014-9

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  47 in total

Review 1.  Oxidative stress and diabetic cardiovascular complications.

Authors:  Desmond Jay; Hirofumi Hitomi; Kathy K Griendling
Journal:  Free Radic Biol Med       Date:  2005-11-10       Impact factor: 7.376

Review 2.  Advanced glycation end products: sparking the development of diabetic vascular injury.

Authors:  Alison Goldin; Joshua A Beckman; Ann Marie Schmidt; Mark A Creager
Journal:  Circulation       Date:  2006-08-08       Impact factor: 29.690

3.  Functional effects of C-type natriuretic peptide and nitric oxide are attenuated in hypertrophic myocytes from pressure-overloaded mouse hearts.

Authors:  Jun Su; Qihang Zhang; Jacob Moalem; James Tse; Peter M Scholz; Harvey R Weiss
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-11-18       Impact factor: 4.733

4.  Myocardial structure and function differ in systolic and diastolic heart failure.

Authors:  Loek van Heerebeek; Attila Borbély; Hans W M Niessen; Jean G F Bronzwaer; Jolanda van der Velden; Ger J M Stienen; Wolfgang A Linke; Gerrit J Laarman; Walter J Paulus
Journal:  Circulation       Date:  2006-04-17       Impact factor: 29.690

5.  Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography.

Authors:  S W Zarich; B E Arbuckle; L R Cohen; M Roberts; R W Nesto
Journal:  J Am Coll Cardiol       Date:  1988-07       Impact factor: 24.094

6.  Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus.

Authors:  John K Boyer; Srihari Thanigaraj; Kenneth B Schechtman; Julio E Pérez
Journal:  Am J Cardiol       Date:  2004-04-01       Impact factor: 2.778

Review 7.  Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.

Authors:  Jasper W L Hartog; Adriaan A Voors; Stephan J L Bakker; Andries J Smit; Dirk J van Veldhuisen
Journal:  Eur J Heart Fail       Date:  2007-12       Impact factor: 15.534

Review 8.  Diabetic cardiomyopathy revisited.

Authors:  Sihem Boudina; E Dale Abel
Journal:  Circulation       Date:  2007-06-26       Impact factor: 29.690

Review 9.  Phosphodiesterase regulation of nitric oxide signaling.

Authors:  David A Kass; Eiki Takimoto; Takahiro Nagayama; Hunter C Champion
Journal:  Cardiovasc Res       Date:  2007-03-02       Impact factor: 10.787

Review 10.  Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.

Authors:  Srinivasa R Kalidindi; W H Wilson Tang; Gary S Francis
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2007-07
View more
  12 in total

1.  Left ventricular function in children and adolescents with type 1 diabetes mellitus.

Authors:  Eun Ha Kim; Yeo Hyang Kim
Journal:  Korean Circ J       Date:  2010-03-24       Impact factor: 3.243

Review 2.  Pharmacotherapy of heart failure with normal ejection fraction (HFNEF)--a systematic review.

Authors:  Sujit Rajagopalan; Anjuman Arora; Nusrat Shafiq; Srinivas Reddy S; Promila Pandhi; Niti Mittal; Samir Malhotra
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

3.  The impact of extra cardiac comorbidities on pressure volume relations in heart failure and preserved ejection fraction.

Authors:  Dmitry Abramov; Kun-Lun He; Jie Wang; Daniel Burkhoff; Mathew S Maurer
Journal:  J Card Fail       Date:  2011-05-06       Impact factor: 5.712

Review 4.  Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension.

Authors:  Federico Luongo; Cristiano Miotti; Gianmarco Scoccia; Silvia Papa; Giovanna Manzi; Nadia Cedrone; Federica Toto; Claudia Malerba; Gennaro Papa; Annalisa Caputo; Giulia Manguso; Francesca Adamo; Dario Vizza Carmine; Roberto Badagliacca
Journal:  Heart Fail Rev       Date:  2022-01-31       Impact factor: 4.214

5.  The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.

Authors:  Que Liu; Lisa Adams; Anatoly Broyde; Rayne Fernandez; Alain D Baron; David G Parkes
Journal:  Cardiovasc Diabetol       Date:  2010-08-03       Impact factor: 9.951

Review 6.  New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.

Authors:  Michele Senni; Walter J Paulus; Antonello Gavazzi; Alan G Fraser; Javier Díez; Scott D Solomon; Otto A Smiseth; Marco Guazzi; Carolyn S P Lam; Aldo P Maggioni; Carsten Tschöpe; Marco Metra; Scott L Hummel; Frank Edelmann; Giuseppe Ambrosio; Andrew J Stewart Coats; Gerasimos S Filippatos; Mihai Gheorghiade; Stefan D Anker; Daniel Levy; Marc A Pfeffer; Wendy Gattis Stough; Burkert M Pieske
Journal:  Eur Heart J       Date:  2014-08-07       Impact factor: 29.983

7.  Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study.

Authors:  Thomas Nyström; Irene Santos-Pardo; Fredric Hedberg; Johan Wardell; Nils Witt; Yang Cao; Leif Bojö; Bo Nilsson; Johan Jendle
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-14       Impact factor: 5.555

8.  The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure.

Authors:  Najah Harouki; Lionel Nicol; Isabelle Remy-Jouet; Jean-Paul Henry; Anais Dumesnil; Annie Lejeune; Sylvanie Renet; Francesca Golding; Zoubir Djerada; Didier Wecker; Virginie Bolduc; Muriel Bouly; Jerome Roussel; Vincent Richard; Paul Mulder
Journal:  JACC Basic Transl Sci       Date:  2017-08-28

Review 9.  Molecular Mechanisms of Retinoid Receptors in Diabetes-Induced Cardiac Remodeling.

Authors:  Jing Pan; Rakeshwar S Guleria; Sen Zhu; Kenneth M Baker
Journal:  J Clin Med       Date:  2014-06-04       Impact factor: 4.241

10.  A diabetes-associated genetic variant is associated with diastolic dysfunction and cardiovascular disease.

Authors:  John Molvin; Amra Jujic; Peter M Nilsson; Margret Leosdottir; Ulf Lindblad; Bledar Daka; Louise Bennet; Lennart Råstam; Valeriya Lyssenko; Martin Magnusson
Journal:  ESC Heart Fail       Date:  2019-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.